Regarding the routine use of cathepsin K IHC in the workup of oncocytic neoplasms: 23 (37%) reported using it only in certain scenarios to arrive at a specific diagnosis, 12 (19%) frequently use cathepsin K IHC in most oncocytic neoplasms, whereas 16 (25%) noted that it was not available in their area of practice (Question #19). Here, CTSK is linked to oncocytic neoplasm.